We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+54.86%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$837M
(+116%)
Cap. Flow
+$592M
Cap. Flow
% of AUM
37.97%
Top 10 Holdings %
Top 10 Hldgs %
44.99%
Holding
85
New
33
Increased
20
Reduced
4
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$94.1M |
| 2 |
Baxter International
BAX
|
+$69.8M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$46.6M |
| 4 |
Arvinas
ARVN
|
+$45.7M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$41.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$49.1M |
| 2 |
Merck
MRK
|
+$37.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$25.5M |
| 4 |
Cardinal Health
CAH
|
+$24.2M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SYNH
26
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $21.3M | 1.37% |
+366,500
| New | +$19.7M |
|
|
BMY.RT
27
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $20.7M | 1.33% |
+5,786,941
| New | +$20.9M |
|
28
BioXcel Therapeutics
BTAI
$27.3M
| $20.6M | 1.32% |
24,256
+11,068
| +84% | +$7.22M |
|
29
Iovance Biotherapeutics
IOVA
$2.24B
| $20.3M | 1.3% |
+738,547
| New | +$24.3M |
|
30
CRISPR Therapeutics
CRSP
$4.63B
| $20.2M | 1.29% |
+274,300
| New | +$16M |
|
|
HARP
31
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $20M | 1.28% |
+120,635
| New | +$18.8M |
|
32
McKesson
MCK
$97.3B
| $19.6M | 1.26% |
128,000
-115,000
| -47% | -$16.6M |
|
33
IDEAYA Biosciences
IDYA
$3.41B
| $18.9M | 1.21% |
+1,331,100
| New | +$10.5M |
|
34
Coherus Oncology
CHRS
$219M
| $18.3M | 1.17% |
1,023,500
+641,500
| +168% | +$10.9M |
|
35
Editas Medicine
EDIT
$442M
| $17.7M | 1.14% |
+600,000
| New | +$15.7M |
|
36
Ascendis Pharma A/S
ASND
$16.5B
| $17.6M | 1.13% |
118,900
+58,900
| +98% | +$8.09M |
|
37
AstraZeneca
AZN
$255B
| $17.2M | 1.11% |
+162,995
| New | +$16.8M |
|
38
Alector
ALEC
$159M
| $16.8M | 1.08% |
686,400
-27,600
| -4% | -$762K |
|
39
Medtronic
MDT
$107B
| $15.9M | 1.02% |
+173,700
| New | +$16.7M |
|
|
PRVL
40
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $15.3M | 0.98% |
+1,028,800
| New | +$15.8M |
|
41
Arcus Biosciences
RCUS
$3.54B
| $14.6M | 0.93% |
+589,000
| New | +$15.9M |
|
|
ADAP
42
DELISTED
Adaptimmune Therapeutics
ADAP
| $14.4M | 0.92% |
+1,438,000
| New | +$9.03M |
|
43
Anika Therapeutics
ANIK
$200M
| $13.7M | 0.88% |
362,490
+194,490
| +116% | +$6.41M |
|
44
Royalty Pharma
RPRX
$25.4B
| $9.71M | 0.62% |
+200,000
| New | +$9.9M |
|
|
SURF
45
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $9.7M | 0.62% |
+1,478,699
| New | +$5.34M |
|
|
DCPH
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $9.33M | 0.6% |
+156,266
| New | +$8.36M |
|
47
Intellia Therapeutics
NTLA
$1.53B
| $8.79M | 0.56% |
+418,178
| New | +$7.1M |
|
48
Verastem
VSTM
$505M
| $7.59M | 0.49% |
367,916
+135,358
| +58% | +$3.58M |
|
|
ONEM
49
DELISTED
1Life Healthcare
ONEM
| $7.26M | 0.47% |
+200,000
| New | +$5.63M |
|
|
AKUS
50
DELISTED
Akouos Inc
AKUS
| $7.09M | 0.45% |
+315,000
| New | +$7.02M |
|
Similar funds
NM
PWAM
CM
LJAC
NI
MCM
TS
TW
Avidity Partners Management's Q2 2020 Portfolio in Review
As of Q2 2020, Avidity Partners Management held 85 positions worth $1.56B, up 116% from $724M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Avidity Partners Management deployed $592M of net new capital in Q2 2020, opening 33 new positions and adding to 20 existing holdings. Its largest new stake was Baxter International: 800,900 shares worth $69M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.
On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $49.1M trimmed.
- Avidity Partners Management's largest Q2 2020 buy was Baxter International: 800,900 shares worth $69M.
- Avidity Partners Management added most to AbbVie in Q2 2020, an estimated $94.1M increase.
- Avidity Partners Management's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $49.1M.
- Avidity Partners Management fully exited Merck in Q2 2020, selling an estimated $37.9M.
- Avidity Partners Management's ten largest holdings make up 45% of its $1.56B portfolio in Q2 2020.
- Avidity Partners Management opened 33 new positions and closed 28 in Q2 2020.
- Avidity Partners Management's portfolio value rose 116% quarter-over-quarter to $1.56B.
Based on Avidity Partners Management's 13F filing for Q2 2020, filed 14 Aug 2020.